Incyte Corporation (NASDAQ:INCY) is one of the most profitable biotech stocks to buy. Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Incyte Corporation (NASDAQ:INCY) on October 22, setting a price target of $104. However, J.P. Morgan analyst Jessica Fye reiterated a Hold rating on Incyte Corporation (NASDAQ:INCY) on October 20. Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds is Buying Fye associated the rating with the company’s market position and cur ...

会议概述 - 公司在ESMO 2025会议上举行实体瘤项目更新会 重点介绍两项研发项目 [1] - 会议议程包括生物学原理介绍 两项数据集解读以及未来计划讨论 [2] - 公司团队由三位核心成员组成 包括首席科学官和早期开发负责人等 [2] 研发项目焦点 - 两项核心实体瘤项目为TGF-beta受体II/PD-1双特异性抗体和KRAS G12D抑制剂 [1] - 两项项目的数据均在ESMO 2025会议上公布 其中一项在周五公布 另一项在会议当天早些时候公布 [1]